How does Insmed (INSM) make money?

Insmed (INSM) generates revenue primarily from Reportable Segment, which accounted for 100% of total revenue in TTM through Q1 2026. The company reported $819.56M in revenue and converted -144.4% of it into net profit, equivalent to roughly −$1.18B in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Insmed (INSM)?

Insmed (INSM) reported a gross profit margin of 81.6% in TTM through Q1 2026, equivalent to $668.40M in gross profit on $819.56M in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Insmed (INSM)?

Insmed (INSM) reported an operating profit margin of -137.7% in TTM through Q1 2026, equivalent to −$1.13B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Insmed (INSM)?

Insmed (INSM) reported a net profit margin of -144.4% in TTM through Q1 2026, equivalent to −$1.18B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Insmed (INSM) profitable?

Insmed (INSM) reported a net loss of $1.18B for TTM through Q1 2026, a net profit margin of -144.4%. Combined operating expenses, interest, and income taxes exceeded revenue, so the period closed in the red on a reported basis.

How much does Insmed (INSM) invest in research and development?

Insmed (INSM) invested $828.00M in research and development during TTM through Q1 2026, roughly 101.0% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does Insmed (INSM) spend on capital expenditures?

Insmed (INSM) spent $55.97M on capital expenditures (CapEx) during TTM through Q1 2026, roughly 6.8% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Insmed (INSM) generate?

Insmed (INSM) generated −$951.63M in free cash flow during TTM through Q1 2026, a free-cash-flow margin of -116.1%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

Where does Insmed (INSM) generate most of its revenue?

UNITED STATES is the largest geographic market for Insmed (INSM), accounting for 74.3% of revenue in the most recent annual filing. The complete regional split — including international markets and any Rest-of-World rollup — is shown in the revenue-by-geography table on this page.

How Insmed Makes Money: 2026 Visual Revenue Map

Insmed (INSM) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported May 7, 2026).

Insmed (INSM) Revenue by Geography — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.

Revenue contribution by geographic region for Insmed (INSM), TTM through Q1 2026
Region	Revenue (USD)	% of total
UNITED STATES	$658.74M	74.3%
Non-US	$189.37M	21.4%
JAPAN	$30.67M	3.5%
Europe And The Rest Of The World	$8.06M	0.9%
Total	$886.84M	100%

UNITED STATES
Non-US
JAPAN
Europe And The Rest Of The World
Total

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, Insmed (INSM) generated 74.3% of revenue from UNITED STATES, followed by Non-US (21.4%) and JAPAN (3.5%).

Frequently asked questions

Data & methodology

Insmed (INSM) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

INSM Overview

Counters

Income Statement

Cash Flow

Capital Return

Forecast & Valuation